Feature | August 27, 2012

Study Shows CT is Superior for Indicating Cardiovascular Risk

A new? study indicates the CT coronary artery calcium score is the superior test for accurately predicting cardiovascular risk and disease in adults at intermediate risk for heart disease

August 27, 2012 - A recent multi-center study, led by researchers from Wake Forest School of Medicine and published in the Journal of the American Medical Association (JAMA) has indicated that computed tomography (CT) scanning of the heart and measuring the coronary artery calcium (CAC) score is the most accurate predictor of cardiovascular disease for individuals at intermediate risk for heart disease.

The study included 1,300 individuals with intermediate cardiovascular risk factors (excluding diabetes) based on the Framingham Risk Score (FRS), who were followed over a period of seven years as part of the National Heart, Lung and Blood Institute's Multi-Ethnic Study of Atherosclerosis (MESA). MESA is an observational study of cardiovascular disease performed at six sites across the United States.
 
Six novel or established markers of heart disease risk were directly compared. These included the CT CAC score, ankle-brachial index, brachial flow mediated dilation, carotid intima-media thickness, high sensitivity C-reactive protein and family history of heart disease. CAC score, determined by CT scan, held the highest predictive association for cardiovascular disease.
 
According to Jeffery J. Carr, M.D., MSc, a co-author on the publication and president-elect of the Society of Cardiovascular Computed Tomography (SCCT), "This work demonstrates that the calcium score outperforms these widely studied tests and even family history in the prediction of future heart attacks and cardiovascular death. For healthcare providers, we have the first direct comparison of these tests. This new evidence will help in advising our patients when additional information is needed to refine an individual's risk of heart disease. In many cases, no additional testing is needed; however, for those important cases where refining our understanding of risk of heart disease is critical to medical decision-making, the cardiac CT measured calcium score is a clear winner as relates to future risk for an individual."
 
Although CAC scans indicated the highest level of accuracy in predicting cardiovascular risk, factors such as cost and the level of risk due to radiation exposure from CT scan will be future considerations in research.
 
For more information, visit www.SCCT.org
 

Related Content

ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting| November 01, 2016
November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...
Overlay Init